One of the newest active mass tort MDLs in the federal court system officially opened its doors in February 2026, and patients who received the Cartiva Synthetic Cartilage Implant for big-toe arthritis are now at a critical decision point. The Cartiva implant lawsuit landscape shifted dramatically when the Judicial Panel on Multidistrict Litigation consolidated all federal cases into a single coordinated proceeding — just months after a sweeping FDA recall confirmed what many injured patients had long suspected: this device was failing at rates no one warned them about.
What Is the Cartiva Synthetic Cartilage Implant?
The Cartiva Synthetic Cartilage Implant (SCI) is a small cylindrical device made from polyvinyl alcohol (PVA) hydrogel — sometimes called a cryogel — designed to treat hallux rigidus, a progressive arthritic condition affecting the first metatarsophalangeal joint at the base of the big toe. Rather than fusing the joint and permanently eliminating motion, the Cartiva SCI was marketed as a motion-preserving alternative: a way to relieve pain while keeping the joint functional.
For patients suffering from debilitating big-toe arthritis, that promise was compelling. Fusion surgery, while effective, permanently eliminates joint movement and comes with its own recovery challenges. The Cartiva implant offered what seemed like a better path forward — until, for thousands of patients, it didn’t. Approximately 22,000 people were implanted with the device before the recall, and later reports suggest the failure rate may affect up to two-thirds of patients — a staggering figure that underlies the scale of potential harm at issue in this litigation. To understand how defective medical device claims are evaluated and what compensation may be available, patients can explore a medical malpractice calculator as a starting point for understanding the scope of their potential damages.
The FDA Recall That Changed Everything
In October 2024, the U.S. Food and Drug Administration issued a Class II recall for the Cartiva Synthetic Cartilage Implant, covering all lots distributed from July 2016 through October 2024. A Class II recall designation means the FDA has determined that use of the device may cause temporary or medically reversible adverse health consequences, though the probability of serious harm is considered lower than a Class I recall.
The language in the FDA recall record is striking in its specificity. According to the recall documentation, the FDA stated that implanted patients may experience a higher-than-expected occurrence of revision, removal, implant subsidence, displacement, pain, nerve damage, or fragmentation. That language — “higher-than-expected” — sits at the heart of every pending Cartiva implant lawsuit: patients allege they were never warned those risks existed at the rates the manufacturer knew or should have known about. For many patients, device failure has meant not just removal surgery but permanent big toe fusion — the very outcome the Cartiva implant was supposed to help them avoid.
MDL 3172: Breaking Down the Federal Consolidation
On February 5, 2026, the Judicial Panel on Multidistrict Litigation formally centralized all federal Cartiva Synthetic Cartilage Implant cases into In re: Cartiva Synthetic Cartilage Implant Products Liability Litigation, MDL No. 3172, master docket 4:26-md-03172-KGB, in the U.S. District Court for the Eastern District of Arkansas. The case is assigned to Judge Kristine G. Baker. As of July 1, 2026, there are 21 pending claims in the litigation — a number that is widely expected to grow substantially as more patients who experienced device failure become aware of their legal options. The first status conference is scheduled for August 19, 2026, marking the official start of coordinated pretrial proceedings and setting the tone for how discovery and case management will unfold in the months ahead.
Who Are the Defendants in the Cartiva Implant Lawsuit?
The defendants named in the Cartiva implant lawsuit are Stryker Corporation and its subsidiary Wright Medical Group N.V. Wright Medical originally developed and commercialized the Cartiva SCI. Stryker acquired Wright Medical in November 2020, inheriting both the product line and — plaintiffs argue — the legal liability that comes with it. Both companies are named in pending actions, and the consolidated MDL proceeding will address their shared and individual roles in the design, manufacture, testing, marketing, and post-market surveillance of the Cartiva device.
Core Allegations and Patient Injuries
Plaintiffs across the country are raising overlapping legal theories against Stryker and Wright Medical. At their core, the claims center on the argument that the Cartiva SCI was defectively designed, that the defendants knew or should have known it was failing at unacceptably high rates, and that patients and their physicians were never adequately warned. With later reports indicating failure may affect up to two-thirds of implanted patients — often requiring removal surgery and, in many cases, permanent big toe fusion — the human cost of these alleged failures is substantial.
Specific injuries reported by claimants include implant subsidence (the device sinking into the bone), displacement or migration of the implant, fragmentation, chronic pain, nerve damage, and the need for revision or removal surgery. For patients who ultimately require fusion after a failed Cartiva implant, the outcome is particularly devastating: they endure multiple surgeries, extended recovery periods, and end up with a permanently fused joint — the very outcome they sought to avoid when they chose the Cartiva device in the first place.
Key Facts and Timeline: Cartiva MDL 3172 at a Glance
- Device: Cartiva Synthetic Cartilage Implant (SCI), a PVA hydrogel implant for hallux rigidus
- Patients implanted before recall: Approximately 22,000
- Recall issued: October 2024 (Class II FDA recall, all lots July 2016–October 2024)
- MDL established: February 5, 2026
- MDL number: MDL 3172, Eastern District of Arkansas
- Presiding judge: Judge Kristine G. Baker
- Pending claims as of July 1, 2026: 21
- First status conference: August 19, 2026
- Defendants: Stryker Corporation and Wright Medical Group N.V.
- Key failure modes: Subsidence, displacement, fragmentation, chronic pain, nerve damage
- Projected settlement range: Approximately $25,000 to $350,000 or more, depending on severity
Where the Litigation Stands Now and What Comes Next
As of mid-2026, the Cartiva MDL is in its earliest organizational phase. With 21 pending claims on record as of July 1, 2026, and the first status conference set for August 19, 2026, the litigation is just beginning its coordinated pretrial journey. That first conference will be critical: Judge Baker will begin setting the procedural roadmap for discovery, bellwether trial selection, and case management orders that will govern the litigation for months or years to come.
What happens next follows a well-established MDL playbook. Lead and liaison counsel will be appointed. The parties will negotiate a discovery schedule and begin exchanging documents related to the design, testing, clinical data, and internal communications surrounding the Cartiva device. Expert witnesses — biomechanical engineers, orthopedic surgeons, regulatory specialists — will be retained and eventually deposed. A handful of representative cases, known as bellwether trials, will be selected to test the strength of both sides’ arguments before a jury. The outcomes of those trials, more than anything else, will drive settlement discussions.
On the question of settlement value, early projections suggest a wide range depending on the specifics of each claimant’s case. Patients who experienced relatively straightforward complications may see values toward the lower end — in the range of approximately $25,000. Those who required multiple surgeries, suffered permanent impairment, or ultimately required big toe fusion after implant failure may see values of $350,000 or more. These figures are projections, not guarantees, and actual outcomes will depend heavily on how the litigation develops and what the bellwether trial results reveal about defendant liability.
For patients who received the Cartiva implant and are experiencing ongoing problems, 2026 is a pivotal year. The statute of limitations — the legal deadline to file a claim — varies by state and typically begins running from the date a patient knew or should have known their device was causing harm. With the MDL now formally open and the recall well-established in the public record, the clock is ticking. Patients who wait too long may lose their right to participate entirely.
Frequently Asked Questions About the Cartiva Implant Lawsuit
Why the Eastern District of Arkansas?
The JPML selected the Eastern District of Arkansas as the home court for MDL 3172 in part because of its geographic accessibility and the court’s capacity to manage complex litigation efficiently. Judge Kristine G. Baker, who was assigned to preside, has experience with multidistrict proceedings. The selection of a particular venue in MDL consolidation is based on factors including judicial resources, proximity to key witnesses and evidence, and the overall administrative capabilities of the court — not necessarily the location where most plaintiffs live.
The JPML Rejected Defendants’ Consolidation Objections
Stryker and Wright Medical opposed centralization of the Cartiva cases into a single MDL, arguing — as defendants often do — that the cases were too factually distinct to benefit from coordinated handling. The JPML disagreed. The panel found that the cases share common questions of fact regarding the design, manufacture, and alleged defects of the Cartiva SCI, making centralization the most efficient path forward for both the courts and the parties. This outcome was not surprising; defendants frequently oppose MDL consolidation because centralization tends to level the playing field and increase plaintiffs’ collective bargaining power.
What Plaintiffs Are Alleging
Plaintiffs in the Cartiva MDL are pursuing claims under several legal theories, which may include: strict products liability for design defect; strict products liability for failure to warn; negligence in design, testing, and post-market surveillance; breach of express and implied warranties; and fraud or fraudulent concealment, based on allegations that the defendants knew about higher-than-expected failure rates and concealed that information from patients and physicians. The precise claims vary by plaintiff and by state law, but the common thread running through all of them is the allegation that Stryker and Wright Medical put a flawed product on the market and failed to give patients the information they needed to make informed decisions.
Injuries Reported by Claimants
The injuries reported by Cartiva implant claimants reflect the range of complications described in the FDA recall notice. Common injuries include implant subsidence (the device settling deeper into the bone than intended), displacement or migration from the implant site, fragmentation of the hydrogel material, persistent and worsening pain at the implant site, nerve damage, and the need for revision surgery. In many cases — potentially affecting up to two-thirds of all implanted patients based on later reports — the ultimate outcome is complete removal of the Cartiva device followed by fusion of the big toe joint. For patients who specifically chose the Cartiva implant to avoid fusion, this outcome represents a particularly significant harm, both physically and psychologically.
Who qualifies to file a Cartiva implant lawsuit in 2026?
Generally speaking, patients who received the Cartiva Synthetic Cartilage Implant and subsequently experienced device failure, required revision or removal surgery, suffered ongoing pain or nerve damage, or underwent big toe fusion may have viable claims. The approximately 22,000 people implanted with the device before the recall represent the potential universe of claimants. Eligibility depends on individual circumstances including the timing of implantation, the nature of complications experienced, and whether the applicable statute of limitations has expired in that patient’s state. Consulting with a mass tort attorney as early as possible is strongly recommended, as waiting can jeopardize eligibility.
What is MDL 3172 and how does it affect individual cases?
MDL 3172 is the formal designation for the consolidated federal proceeding managing all Cartiva implant product liability cases filed in federal court. Multidistrict litigation consolidates cases that share common factual questions — in this instance, questions about the design, manufacture, and alleged defects of the Cartiva SCI — into a single court for pretrial purposes. Individual plaintiffs do not lose their cases; each lawsuit remains a separate action. Consolidation simply means that discovery, expert proceedings, and pretrial motions are handled collectively, which saves time and resources. If cases are not resolved through settlement, they are typically remanded back to the courts where they were originally filed for trial.
What are the main allegations against Stryker and Wright Medical in the Cartiva lawsuit?
The core allegations center on three broad failures. First, plaintiffs allege the Cartiva SCI was defectively designed — that its hydrogel composition and structural properties were inadequate to withstand the mechanical demands of the first metatarsophalangeal joint over time, leading to subsidence, displacement, and fragmentation at rates far higher than what any reasonable patient or physician would have accepted. Second, plaintiffs allege that both Wright Medical and Stryker failed to adequately warn patients and surgeons of these risks, either because they did not know (due to inadequate post-market surveillance) or because they chose not to disclose what they did know. Third, some plaintiffs allege active concealment — that the companies had data pointing to high failure rates and took steps to prevent that information from becoming public until the FDA recall made concealment untenable.
How long will the Cartiva MDL litigation take, and when might there be a settlement?
Mass tort MDLs of this type typically unfold over several years. With the first status conference scheduled for August 19, 2026, the litigation is just entering its organizational phase. Discovery will likely take at least one to two years to complete. Bellwether trials, if they occur, could begin in 2027 or 2028. Global settlement negotiations, if successful, could resolve the bulk of cases before or after bellwether trials, depending on how the evidence develops and how strongly each side believes in its position. Patients who file early are generally better positioned to participate in any global resolution. While projected settlement values ranging from approximately $25,000 to $350,000 or more provide a useful reference point, individual outcomes will depend on case-specific facts and the overall trajectory of the litigation.
Does it matter which state you live in for a Cartiva implant lawsuit?
State of residence can matter in several important ways. First, statutes of limitations — the deadlines to file a lawsuit — vary significantly from state to state, typically ranging from one to six years, and the clock may start running from different triggering events depending on state law. Second, individual state laws governing products liability, failure to warn, and punitive damages differ, which can affect both the claims available to a plaintiff and the potential damages they may recover. However, because MDL 3172 is a federal proceeding, cases from all states are consolidated before Judge Baker in the Eastern District of Arkansas for pretrial purposes. A mass tort attorney with experience in defective medical device litigation can evaluate how your state’s laws apply to your specific situation and ensure your claim is filed within the applicable deadline.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.